All Drug Targets articles – Page 21
-
NewsCancer and the DNA fork reversal mechanism
Researchers find that polymerase epsilon exonuclease is an essential target for cancer diagnosis and treatments that rely on DNA damage.
-
News
Potential new targets for chronic liver disease
Fatty liver disease treatments may become more effective after identification and greater understanding of more drug targets.
-
NewsDirect link between hyperinsulinemia and pancreatic cancer found
Excessive insulin levels in people with obesity and type 2 diabetes overstimulates pancreatic cells, initiating disease.
-
NewsSynthetic proteins key to modular nanoparticle design
Researchers have been able to customise nanoparticles to target biological entities, like tumours and viruses.
-
NewsMechanism that triggers dendritic elongation discovered
Short-chain fatty acids produced by intestinal bacteria initiate dendritic elongation, a mechanism that could be used as a drug target.
-
NewsProtein found to control breast cancer metastasis
Scientists have discovered the motor protein dynein commands movement of cancer cells in soft tissue models, offering new clinical targets.
-
NewsNew molecule disrupts pathways that promote cancer growth
Researchers have discovered a molecule that binds to a cancer cell protein, stopping growth of breast and ovarian tumours.
-
NewsPulmonary ionocytes: unexpected discovery has implications for CF
Researchers found surprising function of pulmonary ionocytes which may affect how cystic fibrosis drugs work.
-
ArticleMicrobiotica: transforming medicine with microbiome magic
In this interview, Anne Neville, Director at Microbiotica, elaborates on the significance of the Microbiotica Culture Collection (MCC) and Microbiotica Reference Genome Database (MRGD), which are fundamental to the development of live biotherapeutic medicines.
-
ArticleEmotional scars: stigma with female adult acne
New research presented at the European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin, Germany, has highlighted a previously underestimated aspect of acne's impact on individuals: its profound influence on social perception.
-
ArticlePatient-derived organoids in disease modelling
In an exclusive interview with Nikki Carter at Molecular Devices, we explore the the power of patient-derived organoids (PDOs) in drug discovery.
-
ArticlePossible adulticidal drugs for Onchocerca volvulus
This article discusses the need for adulticidal drugs to treat Onchocerca volvulus infections, a parasite causing onchocerciasis (river blindness), as the current treatment with ivermectin and surgery presents challenges for affected communities. It highlights research findings on the potential of analgesic medicines to target adult worms and emphasises the importance ...
-
ArticleAddressing increasingly resistant drugs by infectious agents
Infectious agents' drug resistance is a complex challenge affecting survival. Understanding their mechanisms in vectors, the potential of plant-derived treatments, and roles of nucleic acids and biochemical compounds is crucial for effective therapy, requiring collaborative international research through the One Health Initiative.
-
NewsConversations about the NHS: a bold prescription for it’s future
As the NHS celebrates its 75th anniversary, healthcare leaders, policymakers, and practitioners have been sharing their innovative ideas on how to reshape and safeguard its future.
-
WebinarSH2 domains as a target class in cancer and inflammation
New SH2 domain binding assays developed by Eurofins Discovery have been launched to support drug discovery initiatives in the protein-protein interaction space and in targeted protein degradation. We present small molecule case study data for important targets within this target class including STAT Transcription factors and Kinases.
-
ArticleUnleashing the power of AI in target discovery and resilience against disease
In this interview Drug Target Review’s Izzy Wood and Olivia Cavlan, Chief Corporate Development and Strategy Officer at Alchemab Therapeutics Ltd, uncover the untapped potential of AI in target discovery. Alchemab’s revolutionary platform aims to identify common antibodies in resilient individuals and uncover the antigens that contribute to their disease-fighting ...
-
ArticleTargeted protein degradation: turning undruggable targets into druggable targets
Targeted protein degradation (TPD) is a cutting-edge approach in drug discovery that offers a more precise and efficient way to alter cellular pathways, offering the capability to convert 'undruggable targets' into 'druggable targets.' In this article, Drug Target Review’s Izzy Wood interviewed Astellas’ Masahiko Hayakawa, Head of Targeted Protein Degradation, ...
-
ArticleThe promise of iPSC-based multi-cell therapeutics
Drug Target Review’s Taylor Mixides exclusively interviews Matt Angel, PhD, Chief Executive Officer and President of Eterna Therapeutics, about a potential new class of cell therapies that may play an important role in the development of new cancer treatments.
-
ArticleThe evolution and promise of gene therapies
Dr David Baram from gene therapy company EmendoBio provides a snapshot of the history of therapeutic genetic engineering.
-
Whitepaperebook: Fluorescence polarization assays
This ebook outlines the basics of fluorescence polarization and discusses the advantages and limitations of FP-based biochemical assays.